KRAS and neoplasm: Non-standard biomarkers, including DCE, radiomic and texture analysis, and AI-driven features, hold tremendous potential for offering deeper insights into tumour physiology, histology, and genomic characteristics, such as tumour vascularisation, aggressiveness, degree of differentiation, KRAS and MSI status, all of which impact therapy selection.